発達遅滞/知的発達症または神経発達症を有する症例におけるマイクロアレイ染色体検査の検討

Read full text Summarise with VIRAT
Authors: Rei Urushibata, Akane Itoh, Yusuke Ito, Taiju Hayashi, Takuya Hiraide, Tokiko Fukuda
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chromosomal microarray analysis (CMA) enables genome-wide evaluation of copy number variants (CNVs) and has been covered by public health insurance in Japan since 2021. It is now widely used to identify the genetic causes of developmental delay (DD) and neurodevelopmental disorders (NDD). This study aimed to clarify the relationship between clinical features and pathogenic CNVs (pCNVs) in patients with DD and NDD. A total of 53 patients who underwent CMA between October 2021 and August 2024 were retrospectively analyzed. The detection rate of pCNVs and their association with clinical symptoms were evaluated. Pathogenic CNVs were identified in 11 patients (21%). Univariate analysis showed that sleep disorder tended to be more frequent in the pCNV-positive group, although the difference did not remain significant after multiple comparison correction. Logistic regression analysis demonstrated a significant association between the presence of sleep disorder and pCNV positivity, suggesting that patients with sleep disorder had higher odds of harboring pCNVs. These findings suggest a potential relationship between sleep disturbance and pathogenic CNVs, and support the clinical utility of CMA in the genetic evaluation of patients with DD and NDD.

Fields of Study & Subjects

Genomic variations and chromosomal abnormalities Genomics and Rare Diseases Genetics and Neurodevelopmental Disorders

Publication details

Journal / source
Institutional Repositories DataBase (IRDB)
Volume
6
Issue
1
Pages
21–29
Publication date
15 March 2026
Language
JA